China Regenerative Medicine International's disappointing re...
China Regenerative Medicine International's disappointing revenue performance and discouraging growth rates suggest a continuation of its current struggle. Expected industry growth of 82% over the next year outpaces the company's projections.
China Regenerative Medicine International Limited (HKG:8158) Held Back By Insufficient Growth Even After Shares Climb 42%
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment